Showing results (91-100 of 147) with videos related to
Sort By:
Pageof 15
Cancer Medicine|June 4, 2014
T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivoDiana P English, Stefania Bellone, Carlton L Schwab, et al.Molecular Cancer Therapeutics|September 4, 2015
Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In VivoSalvatore Lopez, Emiliano Cocco, Jonathan Black, et al.Cancer|September 25, 2014
Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivoDiana P English, Stefania Bellone, Carlton L Schwab, et al.Gynecologic Oncology|August 12, 2015
Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivoCarlton L Schwab, Diana P English, Jonathan Black, et al.Clinical & Experimental Metastasis|July 5, 2011
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factorEmiliano Cocco, Joyce Varughese, Natalia Buza, et al.Journal of Cancer Research and Clinical Oncology|September 27, 2018
Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancerGary Altwerger, Esther B Florsheim, Gulden Menderes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu ExpressionGulden Menderes, Elena Bonazzoli, Stefania Bellone, et al.Molecular Cancer Therapeutics|January 8, 2010
Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201)Karim El-Sahwi, Stefania Bellone, Emiliano Cocco, et al.Gynecologic Oncology|May 6, 2017
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expressionGulden Menderes, Elena Bonazzoli, Stefania Bellone, et al.Cancer|February 5, 2015
Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumorsMaysa M Abu-Khalaf, Megan A Baumgart, Scott N Gettinger, et al.Pageof 15